Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Perspectives
Open Access

Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19

Matthew A. Sparks, Andrew South, Paul Welling, J. Matt Luther, Jordana Cohen, James Brian Byrd, Louise M. Burrell, Daniel Batlle, Laurie Tomlinson, Vivek Bhalla, Michelle N. Rheault, María José Soler, Sundar Swaminathan and Swapnil Hiremath
CJASN May 2020, 15 (5) 714-716; DOI: https://doi.org/10.2215/CJN.03530320
Matthew A. Sparks
1Division of Nephrology, Department of Medicine, Duke University School of Medicine and Durham VA Health System, Durham, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew A. Sparks
Andrew South
2Section of Nephrology, Department of Pediatrics, Department of Epidemiology & Prevention, Division of Public Health Sciences, Department of Surgery-Hypertension & Vascular Research, Wake Forest School of Medicine, Winston-Salem, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Welling
3Joseph S and Esther Handler Professor, Departments of Medicine (Nephrology) and Physiology, Johns Hopkins School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Matt Luther
4Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt Hypertension Center, Nashville, Tennessee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Matt Luther
Jordana Cohen
5Renal-Electrolyte and Hypertension Division, Department of Medicine and Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jordana Cohen
James Brian Byrd
6Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise M. Burrell
7Department of Medicine, The University of Melbourne, Austin Health, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Batlle
8Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Nephrology, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurie Tomlinson
9London School of Hygiene and Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laurie Tomlinson
Vivek Bhalla
10Stanford Hypertension Center, Stanford University School of Medicine, Stanford, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle N. Rheault
11Division of Pediatric Nephrology, University of Minnesota Masonic Children’s Hospital, Minneapolis, Minnesota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michelle N. Rheault
María José Soler
12Division of Nephrology, Hospital Universitari Vall d’Hebron, Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sundar Swaminathan
13Division of Nephrology and Center for Immunity, Inflammation and Regenerative Medicine, University of Virginia, Charlottesville, Virginia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Swapnil Hiremath
14Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Swapnil Hiremath
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • angiotensin
  • renin angiotensin system
  • virology
  • hypertension
  • ACE inhibitors
  • COVID-19
  • severe acute respiratory syndrome coronavirus 2
  • Renin-Angiotensin System
  • Angiotensin-Converting Enzyme Inhibitors

There has been much speculation in journals, as well as social and traditional media about a link between popularly used classes of drugs that inhibit the renin-angiotensin system (RAS) and novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) infection or coronavirus disease 2019 (COVID-19) disease severity (1,2). After examining the available evidence, we advise that inhibitors of the RAS pathway should be continued in patients with COVID-19 who are taking these drugs for evidence-based indications. The putative link between SARS-CoV-2 angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) can be rationalized by the biology of virus entry (3). The spike protein of SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as a receptor to enter type II pneumocytes or enterocytes (and likely, other cells). Although ACE2 expression is low in lungs where prolyloligopeptidase is the main enzyme that metabolizes angiotensin II to angiotensin (1–7), the presence of ACE2 protein in type II pneumocytes seems important for virus entry (4) (Figure 1). Many concerned physicians and patients are conflicted about how to address ACEis/ARBs vis-à-vis COVID-19. As concerned physicians and scientists working in this area, we summarize the evidence and call for greater understanding and systematic data gathering rather than hasty decision making on the basis of incomplete or inaccurate information or unjustified extrapolations. The current scientific and clinical questions are as follows. Is there a link between hypertension and increased risk of viral infection in humans? Are patients on ACEis/ARBs at increased risk of infection or severity of disease? Does modulation of these drugs (starting, stopping, or continuing) lead to better or worse outcomes in COVID-19?

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Potential effect of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–induced alterations to renin-angiotensin system pathways. SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) via its spike protein and induces internalization and shedding of ACE2, leading to increased angiotensin II (Ang II) and decreased angiotensin (1–7) [Ang-(1–7)] with net increase in inflammation and fibrosis (red) relative to anti-inflammatory and antifibrotic actions (blue). In the left panel, there is no ACEi or ARB; in the right panel, ACEi and/or ARB treatment could diminish effects of Ang II and increase Ang-(1–7) effects, leading to attenuated inflammation and fibrosis. The dashed inset in the right panel represents a theoretical increase in cell membrane expression of ACE2 with ACEi and/or ARB use. AT1R, type 1 angiotensin receptor; AT2R, type 2 angiotensin receptor; MasR, Mas receptor.

A hypothesized relationship between hypertension and COVID-19 mortality is not supported at this time by robust data. It is known that increasing age strongly correlates with hypertension and has been associated with higher mortality from COVID-19. However, none of the reports have adjusted for age or provided age-stratified data for the hypertension and mortality association to understand if this is a robust finding (5).

Some animal studies have demonstrated increased cardiac ACE2 mRNA levels (among other organs, such as kidney vasculature) and activity after ACEi or ARB therapy (6,7). However, others have not shown enhanced ACE2 levels after ACEi or ARB treatment (8). Moreover, data in humans have not consistently shown increased ACE2 levels, and good-quality data are lacking because full-length ACE2 anchored to cells is not easily measurable (9). Moreover, the clinical significance of this biology in COVID-19 infection is uncertain. Thus, these data do not provide sufficient evidence linking RAS inhibitors to upregulation of ACE2 in humans and subsequent SARS-CoV-2 infection.

The complex relationship between viral protein binding to ACE2, RAS components, and viral pathogenicity is not fully understood (Figure 1). Evidence also supports the possibility that ACEis and/or ARBs could reduce the severity of COVID-19 infection. It is also not clear if ARBs could exert preferential effects over ACEis. These questions require more rigorous studies. Severe acute respiratory distress syndrome infection is associated with decreased ACE2 expression in rodent models, and treatment with losartan reduces lung injury (10). Taken together, these gaps in knowledge highlight the urgent need to perform careful clinical and basic research on this topic.

ACEi/ARBs are the most widely used classes of antihypertensive agents, with clinically proven benefits in patients with hypertension, diabetes, heart failure, and CKD. Stopping ACEis and ARBs in asymptomatic, stable patients with heart failure, kidney disease, or hypertension will disrupt clinical care, necessitate extra visits, and increase health care utilization, thus disrupting attempts at social distancing. Preclinical studies (some animal models) actually support the idea that ACEi and/or ARB use could be protective in the setting of viral pneumonias, including coronavirus infection, but no such data are available in humans (10,11). Retrospective and observational data are still being analyzed and reported from the earliest affected regions, and new data are likely to emerge over the coming weeks to months (clinicaltrials.gov: NCT04311177 and NCT04312009). The data are coming fast and rapidly changing, and therefore, we have created a website, which is being updated in real time to provide a more reliable source of information (http://www.nephjc.com/news/covidace2). We believe that it is important to provide the medical community with updates as they emerge on the use of RAS inhibitors in the context of COVID-19.

We strongly suggest to the scientific community to withhold judgement on this issue due to an incomplete understanding of the risk or benefit of these medications. We believe that there is equipoise in this matter, and the only way to establish an evidence base for these decisions is to study these questions in clinical trials or thorough analysis of observational data using appropriate methodology when a trial is not ethical. Randomized clinical trials are in the planning stages at the University of Minnesota. Only through systematic and well planned and executed basic and clinical studies will we answer the scientific and clinical questions above. After reviewing the available data, our conclusion is that the link between hypertension and/or the use of RAS inhibitors (ACEis or ARBs) in patients with SARS-CoV-2 infection and COVID-19 outcomes has not been firmly established. There is no definitive evidence linking RAS inhibition with increased ACE2 expression and subsequent enhanced SARS-CoV-2 infection. Furthermore, there is preclinical data suggesting a potential benefit with RAS inhibition in SARS-CoV-1. Our recommendation is for patients to continue the use of prescribed RAS inhibitors unless there exists an evidence-based indication to discontinue these important life-saving medications.

Disclosures

Dr. Batlle reports nonfinancial support from Angiotensin Therapeutics Inc. In addition, Dr. Batlle is a coinventor of the patent “Active Low Molecular Weight Variants of ACE2” and has also submitted a patent on the potential use of novel angiotensin-converting enzyme 2 proteins for coronavirus infection (issued). Dr. Bhalla reports ownership stock in Pyrames, consultant fees from Maxim Integrated, and service on scientific advisory boards for Relypsa and is a cosite investigator for the Controlling and Lowering Blood Pressure With the MobiusHD-2 trial sponsored by Vascular Dynamics, Inc. outside the submitted work. Dr. Rheault reports other from Retrophin, other from Reata, other from Advicenne, and other from Genentech. Dr. Soler reports personal fees from NovoNordisk, personal fees from Janssen, nonfinancial support from Boehringer, nonfinancial support from Eli Lilly, personal fees from AstraZeneca, and nonfinancial support from Esteve during the conduct of the study. Dr. Welling reports the following disclosures unrelated to the content of the study: American Journal of Physiology scientific advisor/membership and finance committee chair. Dr. Burrell, Dr. Byrd, Dr. Cohen, Dr. Hiremath, Dr. Luther, Dr. South, Dr. Sparks, Dr. Swaminathan, and Dr. Tomlinson have nothing to disclose.

Acknowledgments

This work was supported by NephJC, a not-for-profit organization that supports the work of NephJC and the Nephrology Social Media Collective. Dr. Hiremath, Dr. Rheault, and Dr. Sparks are on the board of directors of NephJC. They receive no monetary support. The content of this article does not reflect the views or opinions of the American Society of Nephrology (ASN) or CJASN. Responsibility for the information and views expressed therein lies entirely with the author(s).

Dr. Batlle reports grants from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) outside of the submitted work. Dr. Byrd reports grants from National Institutes of Health (NIH) and grants from Apple outside the submitted work. Dr. Rheault reports grants from Goldfinch Bio outside the submitted work. Dr. South reports grants from NIH, National Heart, Lung, and Blood Institute (NHLBI); other from NIH, National Heart, Lung, and Blood Institute NHLBI Loan Repayment Program (LRP); and grants from NIH, NIDDK outside of the submitted work. Dr. Sparks received a grant from Renal Research Institute outside of submitted work. Dr. Welling reports the following funding outside of the submitted work: NIDDK and Fondation Leducq. Dr. Swaminathan is supported by NIDDK grant 1RO1DK103043-01A1. Dr. Luther is supported by NIDDK grants DK117875, DK115392, and DK096994, and American Heart Association grants 16GRNT31170033 and 17SFRN33520017 outside of the submitted work. Dr. Bhalla is supported by NIDDK grants DK110385-01A1 and DK079307, and a US-Israel Binational Science Foundation grant outside of the submitted work. Dr. Cohen is supported by NHLBI grant K23-HL133843 outside of the submitted work.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2020 by the American Society of Nephrology

References

  1. ↵
    1. Sommerstein R
    : Rapid response: Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19. BMJ 368: m810, 2020
    OpenUrlFREE Full Text
  2. ↵
    1. Fang L,
    2. Karakiulakis G,
    3. Roth M
    : Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [published online ahead of print March 11, 2020]. Lancet Respir Med pmid:32171062
    OpenUrlPubMed
  3. ↵
    1. Li W,
    2. Moore MJ,
    3. Vasilieva N,
    4. Sui J,
    5. Wong SK,
    6. Berne MA,
    7. Somasundaran M,
    8. Sullivan JL,
    9. Luzuriaga K,
    10. Greenough TC,
    11. Choe H,
    12. Farzan M
    : Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450–454, 2003pmid:14647384
    OpenUrlCrossRefPubMed
  4. ↵
    1. Serfozo P,
    2. Wysocki J,
    3. Gulua G,
    4. Schulze A,
    5. Ye M,
    6. Liu P,
    7. Jin J,
    8. Bader M,
    9. Myöhänen T,
    10. García-Horsman JA,
    11. Batlle D
    : Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension 75: 173–182, 2020pmid:31786979
    OpenUrlCrossRefPubMed
  5. ↵
    1. Zhou F,
    2. Yu T,
    3. Du R,
    4. Fan G,
    5. Liu Y,
    6. Liu Z,
    7. Xiang J,
    8. Wang Y,
    9. Song B,
    10. Gu X,
    11. Guan L,
    12. Wei Y,
    13. Li H,
    14. Wu X,
    15. Xu J,
    16. Tu S,
    17. Zhang Y,
    18. Chen H,
    19. Cao B
    : Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study [published online ahead of print March 11, 2020]. Lancet
  6. ↵
    1. Ocaranza MP,
    2. Godoy I,
    3. Jalil JE,
    4. Varas M,
    5. Collantes P,
    6. Pinto M,
    7. Roman M,
    8. Ramirez C,
    9. Copaja M,
    10. Diaz-Araya G,
    11. Castro P,
    12. Lavandero S
    : Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48: 572–578, 2006pmid:16908757
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ferrario CM,
    2. Jessup J,
    3. Chappell MC,
    4. Averill DB,
    5. Brosnihan KB,
    6. Tallant EA,
    7. Diz DI,
    8. Gallagher PE
    : Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605–2610, 2005pmid:15897343
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Burrell LM,
    2. Risvanis J,
    3. Kubota E,
    4. Dean RG,
    5. MacDonald PS,
    6. Lu S,
    7. Tikellis C,
    8. Grant SL,
    9. Lew RA,
    10. Smith AI,
    11. Cooper ME,
    12. Johnston CI
    : Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26: 369–375, 2005pmid:15671045
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ramchand J,
    2. Patel SK,
    3. Srivastava PM,
    4. Farouque O,
    5. Burrell LM
    : Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One 13: e0198144, 2018pmid:29897923
    OpenUrlCrossRefPubMed
  10. ↵
    1. Kuba K,
    2. Imai Y,
    3. Rao S,
    4. Gao H,
    5. Guo F,
    6. Guan B,
    7. Huan Y,
    8. Yang P,
    9. Zhang Y,
    10. Deng W,
    11. Bao L,
    12. Zhang B,
    13. Liu G,
    14. Wang Z,
    15. Chappell M,
    16. Liu Y,
    17. Zheng D,
    18. Leibbrandt A,
    19. Wada T,
    20. Slutsky AS,
    21. Liu D,
    22. Qin C,
    23. Jiang C,
    24. Penninger JM
    : A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11: 875–879, 2005pmid:16007097
    OpenUrlCrossRefPubMed
  11. ↵
    1. Yang P,
    2. Gu H,
    3. Zhao Z,
    4. Wang W,
    5. Cao B,
    6. Lai C,
    7. Yang X,
    8. Zhang L,
    9. Duan Y,
    10. Zhang S,
    11. Chen W,
    12. Zhen W,
    13. Cai M,
    14. Penninger JM,
    15. Jiang C,
    16. Wang X
    : Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 4: 7027, 2014pmid:25391767
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 15 (5)
Clinical Journal of the American Society of Nephrology
Vol. 15, Issue 5
May 07, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19
Matthew A. Sparks, Andrew South, Paul Welling, J. Matt Luther, Jordana Cohen, James Brian Byrd, Louise M. Burrell, Daniel Batlle, Laurie Tomlinson, Vivek Bhalla, Michelle N. Rheault, María José Soler, Sundar Swaminathan, Swapnil Hiremath
CJASN May 2020, 15 (5) 714-716; DOI: 10.2215/CJN.03530320

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19
Matthew A. Sparks, Andrew South, Paul Welling, J. Matt Luther, Jordana Cohen, James Brian Byrd, Louise M. Burrell, Daniel Batlle, Laurie Tomlinson, Vivek Bhalla, Michelle N. Rheault, María José Soler, Sundar Swaminathan, Swapnil Hiremath
CJASN May 2020, 15 (5) 714-716; DOI: 10.2215/CJN.03530320
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Reducing the Burden of CKD among Latinx
  • Social Determinants of Health in People with Kidney Disease
  • Personal Experiences of Patients in the Interaction of Culture and Kidney Disease
Show more Perspectives

Cited By...

  • Hypertension and renin-angiotensin system blockers are not associated with expression of Angiotensin Converting Enzyme 2 (ACE2) in the kidney
  • ACE inhibitors, AT1 receptor blockers and COVID-19: clinical epidemiology evidences for a continuation of treatments. The ACER-COVID study
  • Clinical Characteristics and Trends in Heart Failure Hospitalizations: An Australian Experience During the COVID-19 Lockdown
  • Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection
  • Designed Variants of ACE2-Fc that Decouple Anti-SARS-CoV-2 Activities from Unwanted Cardiovascular Effects
  • Authors Reply
  • Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • angiotensin
  • renin angiotensin system
  • virology
  • hypertension
  • ACE inhibitors
  • COVID-19
  • severe acute respiratory syndrome coronavirus 2
  • Renin-Angiotensin System
  • Angiotensin-Converting Enzyme Inhibitors

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire